Brainsway Ltd (BWAY)
BrainsWay Ltd. is a depositary receipt listed on NASDAQ that represents common stock of BrainsWay Ltd., a healthcare equipment and supplies company focused on noninvasive neurostimulation treatments. Through its Deep Transcranial Magnetic Stimulation platform, the company develops and sells therapies used in the treatment of a range of mental health and neurological conditions, including major depressive disorder, anxious depression, obsessive-compulsive disorder, smoking addiction, bipolar disorder, post-traumatic stress disorder, schizophrenia, Alzheimer’s disease, autism, chronic pain, multiple sclerosis, post-stroke rehabilitation, and Parkinson’s disease. Its customers include doctors, hospitals, and medical centers in psychiatry. BrainsWay was founded in 2003 and is headquartered in Jerusalem, Israel. The listed security is an ADR, rather than a direct common equity listing.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-BWAY
|
$11.37
|
-31.3% Downside
|
Overvalued
|
$17.67
|
6.7% Upside
|
Fair
|
Great
|
—
|
—
|
—
|
0.0%
|
August 12, 2026
|
75.5x
|
8.7x
|
11.8x
|
667.4 M
|
584 M
|
1.0%
|
74.5%
|
6.1
|
—
|
132.3%
|
